Adam M Brufsky

Summary

Affiliation: University of Pittsburgh
Country: USA

Publications

  1. doi request reprint How to develop and deliver pathway-based care
    Adam Brufsky
    University of Pittsburgh, Magee Women s Hospital, 300 Halket Street, Suite 4628, Pittsburgh, PA 15213, USA
    Hematol Oncol Clin North Am 27:843-50, x. 2013
  2. pmc Prognostic utility of the breast cancer index and comparison to Adjuvant! Online in a clinical case series of early breast cancer
    Rachel C Jankowitz
    Department of Medicine, Division of Hematology Oncology, UPMC, University of Pittsburgh Cancer Institute, 300 Halket Street, Suite 4628, Pittsburgh, PA 15213, USA
    Breast Cancer Res 13:R98. 2011
  3. doi request reprint Second-line bevacizumab-containing therapy in patients with triple-negative breast cancer: subgroup analysis of the RIBBON-2 trial
    Adam Brufsky
    Magee Women s Hospital, University of Pittsburgh School of Medicine, 300 Halket Street, Suite 4628, Pittsburgh, PA 15213, USA
    Breast Cancer Res Treat 133:1067-75. 2012
  4. doi request reprint Final 5-year results of Z-FAST trial: adjuvant zoledronic acid maintains bone mass in postmenopausal breast cancer patients receiving letrozole
    Adam M Brufsky
    Magee Womens Hospital, University of Pittsburgh Cancer Institute, Pittsburgh, Pennsylvania, USA
    Cancer 118:1192-201. 2012
  5. ncbi request reprint Zoledronic acid inhibits adjuvant letrozole-induced bone loss in postmenopausal women with early breast cancer
    Adam Brufsky
    Magee Womens Hospital, University of Pittsburgh Cancer Institute, Pittsburgh, PA 15123, USA
    J Clin Oncol 25:829-36. 2007
  6. ncbi request reprint Managing bone loss in women with early-stage breast cancer receiving aromatase inhibitors
    Adam M Brufsky
    Magee Women s Hospital of the University of Pittsburgh Medical Center, 300 Halket Street, Pittsburgh, PA 15213, USA
    Clin Breast Cancer 8:S22-34. 2007
  7. doi request reprint Trastuzumab-based therapy for patients with HER2-positive breast cancer: from early scientific development to foundation of care
    Adam Brufsky
    School of Medicine, University of Pittsburgh Cancer Institute, Magee Women s Hospital, Pittsburgh, PA, USA
    Am J Clin Oncol 33:186-95. 2010
  8. doi request reprint Central nervous system metastases in patients with HER2-positive metastatic breast cancer: incidence, treatment, and survival in patients from registHER
    Adam M Brufsky
    University of Pittsburgh Cancer Center, Pittsburgh, Pennsylvania 15213, USA
    Clin Cancer Res 17:4834-43. 2011
  9. ncbi request reprint Bone health issues in women with early-stage breast cancer receiving aromatase inhibitors
    Adam M Brufsky
    Magee Womens Hospital of University of Pittsburgh Medical Center, Suite 4628, 300 Halket Street, Pittsburgh, PA 15213, USA
    Curr Oncol Rep 10:18-26. 2008
  10. doi request reprint Zoledronic acid for cancer therapy--induced and postmenopausal bone loss
    Adam M Brufsky
    Magee Womens Hospital, University of Pittsburgh Medical Center, Pittsburgh, PA 15213, USA
    Expert Opin Pharmacother 9:1013-28. 2008

Detail Information

Publications57

  1. doi request reprint How to develop and deliver pathway-based care
    Adam Brufsky
    University of Pittsburgh, Magee Women s Hospital, 300 Halket Street, Suite 4628, Pittsburgh, PA 15213, USA
    Hematol Oncol Clin North Am 27:843-50, x. 2013
    ..Oncologists must take an active role in defining and implementing cost-effective care for patients, payers, and referring physicians. ..
  2. pmc Prognostic utility of the breast cancer index and comparison to Adjuvant! Online in a clinical case series of early breast cancer
    Rachel C Jankowitz
    Department of Medicine, Division of Hematology Oncology, UPMC, University of Pittsburgh Cancer Institute, 300 Halket Street, Suite 4628, Pittsburgh, PA 15213, USA
    Breast Cancer Res 13:R98. 2011
    ..Objectives of the current study were to validate BCI in a clinical case series and to compare the prognostic utility of BCI and Adjuvant!Online (AO)...
  3. doi request reprint Second-line bevacizumab-containing therapy in patients with triple-negative breast cancer: subgroup analysis of the RIBBON-2 trial
    Adam Brufsky
    Magee Women s Hospital, University of Pittsburgh School of Medicine, 300 Halket Street, Suite 4628, Pittsburgh, PA 15213, USA
    Breast Cancer Res Treat 133:1067-75. 2012
    ..Patients with metastatic TNBC derived significant PFS and response benefits from the combination of bevacizumab with second-line chemotherapy. Despite the small sample size and immature data, there was a trend toward improved OS...
  4. doi request reprint Final 5-year results of Z-FAST trial: adjuvant zoledronic acid maintains bone mass in postmenopausal breast cancer patients receiving letrozole
    Adam M Brufsky
    Magee Womens Hospital, University of Pittsburgh Cancer Institute, Pittsburgh, Pennsylvania, USA
    Cancer 118:1192-201. 2012
    ..Zoledronic acid inhibits osteoclastic bone resorption, is effective in maintaining bone health, and may therefore be beneficial in this setting...
  5. ncbi request reprint Zoledronic acid inhibits adjuvant letrozole-induced bone loss in postmenopausal women with early breast cancer
    Adam Brufsky
    Magee Womens Hospital, University of Pittsburgh Cancer Institute, Pittsburgh, PA 15123, USA
    J Clin Oncol 25:829-36. 2007
    ..The addition of zoledronic acid to adjuvant letrozole therapy may protect against bone loss...
  6. ncbi request reprint Managing bone loss in women with early-stage breast cancer receiving aromatase inhibitors
    Adam M Brufsky
    Magee Women s Hospital of the University of Pittsburgh Medical Center, 300 Halket Street, Pittsburgh, PA 15213, USA
    Clin Breast Cancer 8:S22-34. 2007
    ..Until these data become available, balancing the safety concerns with the potential benefits of I.V. bisphosphonates to minimize or prevent AI-induced bone loss in women with early-stage breast cancer is required...
  7. doi request reprint Trastuzumab-based therapy for patients with HER2-positive breast cancer: from early scientific development to foundation of care
    Adam Brufsky
    School of Medicine, University of Pittsburgh Cancer Institute, Magee Women s Hospital, Pittsburgh, PA, USA
    Am J Clin Oncol 33:186-95. 2010
    ..New approaches to maximize the clinical benefit of trastuzumab-based therapy are under investigation and include novel combinations with other targeted therapies such as bevacizumab, pertuzumab, and lapatinib...
  8. doi request reprint Central nervous system metastases in patients with HER2-positive metastatic breast cancer: incidence, treatment, and survival in patients from registHER
    Adam M Brufsky
    University of Pittsburgh Cancer Center, Pittsburgh, Pennsylvania 15213, USA
    Clin Cancer Res 17:4834-43. 2011
    ..registHER is a prospective, observational study of 1,023 newly diagnosed HER2-positive metastatic breast cancer (MBC) patients...
  9. ncbi request reprint Bone health issues in women with early-stage breast cancer receiving aromatase inhibitors
    Adam M Brufsky
    Magee Womens Hospital of University of Pittsburgh Medical Center, Suite 4628, 300 Halket Street, Pittsburgh, PA 15213, USA
    Curr Oncol Rep 10:18-26. 2008
    ..However, several large studies to clarify the role of bisphosphonates in maintaining or improving bone health in these women are under way...
  10. doi request reprint Zoledronic acid for cancer therapy--induced and postmenopausal bone loss
    Adam M Brufsky
    Magee Womens Hospital, University of Pittsburgh Medical Center, Pittsburgh, PA 15213, USA
    Expert Opin Pharmacother 9:1013-28. 2008
    ..Cancer therapy-induced bone loss (CTIBL) and bone loss in postmenopausal (PMW) increase fracture risk...
  11. doi request reprint Zoledronic acid effectively prevents aromatase inhibitor-associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole: Z-FAST study 36-month follow-up results
    Adam M Brufsky
    Magee Womens Hospital, University of Pittsburgh Cancer Institute, Pittsburgh, PA 15123, USA
    Clin Breast Cancer 9:77-85. 2009
    ..The ongoing Zometa-Femara Adjuvant Synergy Trial (Z-FAST) is evaluating the efficacy and safety of zoledronic acid in preventing such bone loss...
  12. doi request reprint Integrated analysis of zoledronic acid for prevention of aromatase inhibitor-associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole
    Adam Brufsky
    Magee Womens Hospital, Pittsburgh, Pennsylvania 15123, USA
    Oncologist 13:503-14. 2008
    ....
  13. doi request reprint RIBBON-2: a randomized, double-blind, placebo-controlled, phase III trial evaluating the efficacy and safety of bevacizumab in combination with chemotherapy for second-line treatment of human epidermal growth factor receptor 2-negative metastatic breast c
    Adam M Brufsky
    University of Pittsburgh, 300 Halket St, Suite 4628, Pittsburgh, PA 15213, USA
    J Clin Oncol 29:4286-93. 2011
    ....
  14. doi request reprint Cancer treatment-induced bone loss: pathophysiology and clinical perspectives
    Adam M Brufsky
    University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania 15213, USA
    Oncologist 13:187-95. 2008
    ..Such agents have the potential to delay or prevent CTIBL in patients receiving hormonal therapies...
  15. doi request reprint A randomized phase II study of paclitaxel and bevacizumab with and without gemcitabine as first-line treatment for metastatic breast cancer
    Adam Brufsky
    University of Pittsburgh School of Medicine, 300 Halket St, Pittsburgh, PA 15213, USA
    Clin Breast Cancer 11:211-20. 2011
    ..The addition of bevacizumab to paclitaxel improved progression-free survival (PFS) of patients with metastatic breast cancer (MBC). We examined the efficacy and safety of adding gemcitabine to paclitaxel/bevacizumab (PB)...
  16. pmc Memory impairments with adjuvant anastrozole versus tamoxifen in women with early-stage breast cancer
    Catherine M Bender
    University of Pittsburgh School of Nursing, Pittsburgh, PA 15261, USA
    Menopause 14:995-8. 2007
    ..We hypothesized, therefore, that anastrozole would have a more profound effect on cognitive function than tamoxifen, a mixed estrogen agonist/antagonist...
  17. doi request reprint Lapatinib as a component of neoadjuvant therapy for HER2-positive operable breast cancer (NSABP protocol B-41): an open-label, randomised phase 3 trial
    Andre Robidoux
    National Surgical Adjuvant Breast and Bowel Project NSABP, Pittsburgh, PA, USA Centre Hospitalier de l Université de Montréal, Montreal, QC, Canada Electronic address
    Lancet Oncol 14:1183-92. 2013
    ....
  18. pmc What do perceived cognitive problems reflect?
    Catherine M Bender
    University of Pittsburgh School of Nursing, 3500 Victoria Street, Suite 415, Pittsburgh, PA 15261, USA
    J Support Oncol 6:238-42. 2008
    ..At a minimum, our results indicated that women's complaints of cognitive problems should prompt additional assessment to clarify the bases of the problem and initiate appropriate intervention...
  19. doi request reprint Immunohistochemical surrogate markers of breast cancer molecular classes predicts response to neoadjuvant chemotherapy: a single institutional experience with 359 cases
    Rohit Bhargava
    Department of Pathology, Magee Womens Hospital of UPMC, 300 Halket Street, Pittsburgh, PA 15213, USA
    Cancer 116:1431-9. 2010
    ..We hypothesize that a similar response could be predicted using semiquantitative immunohistochemistry for estrogen receptors (ER), progesterone receptors (PR), and human epidermal growth factor receptor 2 (HER2)...
  20. doi request reprint Semiquantitative hormone receptor level influences response to trastuzumab-containing neoadjuvant chemotherapy in HER2-positive breast cancer
    Rohit Bhargava
    Department of Pathology, Magee Womens Hospital, University of Pittsburgh Medical Center, Pittsburgh, PA 15213, USA
    Mod Pathol 24:367-74. 2011
    ..This information can be utilized to counsel patients considered for neoadjuvant chemotherapy and the same principle could be applied in the adjuvant setting...
  21. pmc Definitive results of a phase III adjuvant trial comparing three chemotherapy regimens in women with operable, node-positive breast cancer: the NSABP B-38 trial
    Sandra M Swain
    Sandra M Swain, Gong Tang, Charles E Geyer Jr, Priya Rastogi, James N Atkins, Paul P Donnellan, Louis Fehrenbacher, Catherine A Azar, André Robidoux, Jonathan A Polikoff, Adam M Brufsky, David D Biggs, Edward A Levine, John L Zapas, Louise Provencher, Soonmyung Paik, Joseph P Costantino, Eleftherios P Mamounas, and Norman Wolmark, National Surgical Adjuvant Breast and Bowel Project NSABP Norman Wolmark, Allegheny General Hospital, Allegheny Health Network Gong Tang and Joseph P Costantino, NSABP Biostatistical Center and University of Pittsburgh Graduate School of Public Health Priya Rastogi, University of Pittsburgh Cancer Institute Adam M Brufsky, Magee Womens Hospital of University of Pittsburgh Medical Center, Pittsburgh, PA Sandra M Swain, Medstar Washington Hospital Center, Washington, DC Charles E Geyer Jr, Virginia Commonwealth University, Richmond, VA James N Atkins, UCLA-SFVP Department of Medicine
    J Clin Oncol 31:3197-204. 2013
    ....
  22. doi request reprint Stereotactic radiosurgery as primary and salvage treatment for brain metastases from breast cancer. Clinical article
    Douglas Kondziolka
    Department of Neurological Surgery, University of Pittsburgh, Pittsburgh, Pennsylvania15213, USA
    J Neurosurg 114:792-800. 2011
    ..To evaluate the role of stereotactic radiosurgery (SRS) in the management of brain metastases from breast cancer, the authors assessed clinical outcomes and prognostic factors for survival...
  23. ncbi request reprint Long-term survivors after gamma knife radiosurgery for brain metastases
    Douglas Kondziolka
    Department of Neurological Surgery, University of Pittsburgh School of Medicine, University of Pittsburgh Medical Center, PA 15213, USA
    Cancer 104:2784-91. 2005
    ..The authors evaluated all brain metastasis in patients who lived for > or = 4 years after radiosurgery to determine clinical and treatment patterns potentially responsible for their outcome...
  24. doi request reprint The evolving role of bone-conserving therapy in patients with breast cancer
    Adam M Brufsky
    University of Pittsburgh Medical Center, PA, USA
    Semin Oncol 37:S12-9. 2010
    ..Overall, these data warrant further consideration of the role of bisphosphonates in BC. Ongoing studies will further investigate the bone-protective and potential anticancer benefits of BPs across all stages of breast disease...
  25. doi request reprint Oral clodronate for adjuvant treatment of operable breast cancer (National Surgical Adjuvant Breast and Bowel Project protocol B-34): a multicentre, placebo-controlled, randomised trial
    Alexander H G Paterson
    National Surgical Adjuvant Breast and Bowel Project, Pittsburgh, PA, USA
    Lancet Oncol 13:734-42. 2012
    ..The National Surgical Adjuvant Breast and Bowel Project (NSABP) protocol B-34 aims to ascertain whether oral clodronate can improve outcomes in women with primary breast cancer...
  26. doi request reprint Localization of CD44 and CD90 positive cells to the invasive front of breast tumors
    Vera S Donnenberg
    University of Pittsburgh Cancer Center, Pittsburgh, Pennsylvania, USA
    Cytometry B Clin Cytom 78:287-301. 2010
    ..A variety of markers have been proposed to identify breast cancer stem cells. Here, we used immunohistostaining and flow cytometry to analyze their interrelationships and to sort cells for tumorigenicity studies...
  27. ncbi request reprint The role of bisphosphonates in the adjuvant setting for breast cancer
    Jennifer G Reeder
    Division of Hematology Oncology, Magee Womens Hospital, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania 15232, USA
    Oncology (Williston Park) 24:462-7, 475. 2010
    ..Data from a number of ongoing trials will further elucidate the role of bisphosphonates in the adjuvant setting over the next few years...
  28. pmc Does lifetime exposure to hormones predict pretreatment cognitive function in women before adjuvant therapy for breast cancer?
    Catherine M Bender
    University of Pittsburgh School of Nursing, Pittsburgh, PA 15261, USA
    Menopause 20:922-9. 2013
    ..The basis for this may partly include hormone exposure during the course of a woman's life...
  29. ncbi request reprint Cognitive impairment associated with adjuvant therapy in breast cancer
    Catherine M Bender
    University of Pittsburgh School of Nursing, Victoria Building, Suite 415, Pittsburgh, PA 15261, USA
    Psychooncology 15:422-30. 2006
    ..In conclusion, adjuvant chemotherapy in women with breast cancer can be associated with deteriorations in memory and this may persist over time. The addition of tamoxifen may lead to more widespread memory deficits...
  30. ncbi request reprint Low overexpression of HER-2/neu in advanced colorectal cancer limits the usefulness of trastuzumab (Herceptin) and irinotecan as therapy. A phase II trial
    Ramesh K Ramanathan
    University of Pittsburgh Cancer Institute, Pittsburgh, Pennsylvania 15232, USA
    Cancer Invest 22:858-65. 2004
    ....
  31. ncbi request reprint Phyllodes tumor: a clinicopathologic and immunohistochemical study of 30 cases
    Nicole Nicosia Esposito
    Department of Pathology, University of Pittsburgh, Pittsburgh, PA 15213, USA
    Arch Pathol Lab Med 130:1516-21. 2006
    ..However, histologic classification does not always predict outcome. Objective.-To determine the prognostic value of a variety of clinicopathologic features and immunoreactivities in PTs...
  32. ncbi request reprint Management of cancer-treatment-induced bone loss in postmenopausal women undergoing adjuvant breast cancer therapy: a Z-FAST update
    Adam Brufsky
    Magee UPCI Breast Program, University of Pittsburgh Cancer Institute, Pittsburgh, PA 15213 3180, USA
    Semin Oncol 33:S13-7. 2006
    ..Combining the anticancer efficacy of letrozole with the bone-protective effect of zoledronic acid may be a successful treatment in this setting...
  33. ncbi request reprint The nurse as principal investigator in a pharmaceutically sponsored drug trial: considerations and challenges
    Margaret Q Rosenzweig
    School of Nursing, University of Pittsburgh, Pittsburgh, PA, USA
    Oncol Nurs Forum 32:293-9. 2005
    ..To discuss the process, considerations, benefits, and challenges of the nurse as principal investigator in a cancer care drug trial...
  34. doi request reprint Risedronate prevents bone loss in breast cancer survivors: a 2-year, randomized, double-blind, placebo-controlled clinical trial
    Susan L Greenspan
    Department of Medicine, University of Pittsburgh, 3471 Fifth Ave, Kaufmann Suite 1110, Pittsburgh, PA 15213, USA
    J Clin Oncol 26:2644-52. 2008
    ..Limited data are available on the efficacy of oral bisphosphonate therapy in breast cancer survivors. Our goal was to examine prevention of breast cancer-related bone loss in this cohort...
  35. pmc CSPG4 protein as a new target for the antibody-based immunotherapy of triple-negative breast cancer
    Xinhui Wang
    University of Pittsburgh Cancer Institute, Pittsburgh, PA 15213, USA
    J Natl Cancer Inst 102:1496-512. 2010
    ..The lack of effective therapy for triple-negative breast cancer (TNBC) prompted us to examine whether CSPG4 is expressed in TNBC and can be targeted with CSPG4-specific mAb...
  36. ncbi request reprint Prevention of bone loss in survivors of breast cancer: A randomized, double-blind, placebo-controlled clinical trial
    Susan L Greenspan
    Department of Medicine, University of Pittsburgh, 3471 Fifth Avenue, Suite 1110, Pittsburgh, Pennsylvania 15213 3221, USA
    J Clin Endocrinol Metab 92:131-6. 2007
    ..Few data are available on the safety and efficacy of once-weekly oral bisphosphonate therapy in breast cancer survivors...
  37. ncbi request reprint Phase I pharmacokinetic-pharmacodynamic study of 17-(allylamino)-17-demethoxygeldanamycin (17AAG, NSC 330507), a novel inhibitor of heat shock protein 90, in patients with refractory advanced cancers
    Ramesh K Ramanathan
    Molecular Therapeutics Drug Discovery Program, Biostatistics Department, Graduate School of Public Health, and Biostatistics Facility, University of Pittsburgh Cancer Institute, PA 15232, USA
    Clin Cancer Res 11:3385-91. 2005
    ..We did a phase I study of 17AAG to establish the dose-limiting toxicity and maximum tolerated dose and to characterize 17AAG pharmacokinetics and pharmacodynamics...
  38. pmc Adjuvant treatment of HER2-positive breast cancer: winning efforts continue to improve HER2-positive patient outcome long-term
    Rachel C Jankowitz
    University of Pittsburgh Cancer Institute, Magee Women s Hospital, 300 Halket Street, Suite 4628, Pittsburgh, PA 15213, USA
    Breast Cancer Res 14:308. 2012
    ..Ongoing study is needed to identify markers of resistance to trastuzumab and incorporate newer agents in the adjuvant setting in order to further decrease rates of distant recurrence and death from HER2-positive breast cancer...
  39. ncbi request reprint Randomized controlled trial of the Breast Cancer Recovery Program for women with breast cancer-related lymphedema
    Marjorie K McClure
    Magee Women s Research Institute, Pittsburgh, PA, USA
    Am J Occup Ther 64:59-72. 2010
    ..Adherence was high for this safe and effective program, which improved lymphedema physical and emotional symptoms...
  40. ncbi request reprint The decision to prematurely terminate a trial of R-HuEPO due to thrombotic events
    Margaret Q Rosenzweig
    Department of Acute Tertiary Care, University of Pittsburgh School of Nursing, Pittsburgh, Pennsylvania 15261, USA
    J Pain Symptom Manage 27:185-90. 2004
    ..This may relate to the administration of r-HuEPO in this high-risk population, but the small sample size and possible predisposing risk factors preclude definitive conclusions...
  41. pmc Biomarker profile in breast carcinomas presenting with bone metastasis
    Olga L Bohn
    Department of Pathology, Magee Women s Hospital of University of Pittsburgh Medical Center, Pittsburgh, PA 15213 3180, USA
    Int J Clin Exp Pathol 3:139-46. 2009
    ..The high morbidity associated to metastatic breast cancer prompts the identification of predictive biomarkers of relapse of breast tumors to categorize patients at high risk of bone metastasis and serve as targeted therapy...
  42. doi request reprint Adjuvant endocrine therapy for premenopausal women with breast cancer
    Shannon Puhalla
    University of Pittsburgh, Cancer Institute, Pittsburgh, PA 15232, USA
    Breast 18:S122-30. 2009
    ..This paper serves as a comprehensive review of the substantial data in the adjuvant treatment of premenopausal, hormone receptor-positive women with breast cancer...
  43. ncbi request reprint Hormone receptor status does not affect the clinical benefit of trastuzumab therapy for patients with metastatic breast cancer
    Adam Brufsky
    Pittsburgh Cancer Institute, Pittsburgh, PA, USA
    Clin Breast Cancer 6:247-52. 2005
    ..The impact of HR status on the clinical outcome of patients with HER2-overexpressing disease treated with the monoclonal antibody trastuzumab is unknown...
  44. ncbi request reprint Evaluation of the OncoTCap (Oncology Thinking Cap) simulation in teaching medical students about clinical trials: some successes and some surprises
    Roger S Day
    Department of Biostatistics, University of Pittsburgh, Sterling Plaza, 201 North Craig Street, Suite 325, Pittsburgh, PA 15213, USA
    J Cancer Educ 19:149-55. 2004
    ..A training workshop for cancer clinical trials was developed utilizing a computer simulation encompassing cancer biology, metabolism, adverse effects, and clinical trial design...
  45. doi request reprint Long-term treatment with intravenous bisphosphonates in metastatic breast cancer: a retrospective study
    Adam M Brufsky
    Hematology Oncology, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania
    Breast J 19:504-11. 2013
    ..Times to ONJ or renal impairment also were similar across intravenous bisphosphonate type. Long-term (≥24 months) intravenous bisphosphonate use in metastatic BC is well tolerated, with low incidences of ONJ and renal impairment...
  46. doi request reprint Breast cancer index identifies early-stage estrogen receptor-positive breast cancer patients at risk for early- and late-distant recurrence
    Yi Zhang
    bioTheranostics, Inc, San Diego, California, USA
    Clin Cancer Res 19:4196-205. 2013
    ..Residual risk of relapse remains a substantial concern for patients with hormone receptor-positive breast cancer, with approximately half of all disease recurrences occurring after five years of adjuvant antiestrogen therapy...
  47. pmc Connexin 47 mutations increase risk for secondary lymphedema following breast cancer treatment
    David N Finegold
    Department of Pediatrics, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania 15261, USA
    Clin Cancer Res 18:2382-90. 2012
    ..The potential contribution of genetic susceptibility to risk of developing secondary lymphedema following surgical trauma, radiation, and other tissue insults has not been studied...
  48. ncbi request reprint Single-fraction radiosurgery for the treatment of spinal breast metastases
    Peter C Gerszten
    Department of Neurological Surgery, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania 15213, USA
    Cancer 104:2244-54. 2005
    ..This study evaluated the clinical efficacy of the treatment of spinal breast carcinoma metastases with a single-fraction radiosurgical technique...
  49. ncbi request reprint High prevalence of screening-detected prostate cancer among Afro-Caribbeans: the Tobago Prostate Cancer Survey
    Clareann H Bunker
    Department of Epidemiology, University of Pittsburgh, Pittsburgh, Pennsylvania 15261, USA
    Cancer Epidemiol Biomarkers Prev 11:726-9. 2002
    ..These data support the hypothesis that populations of African descent share genetic and/or lifestyle factors that contribute to their elevated risk for prostate cancer...
  50. doi request reprint Histopathologic variables predict Oncotype DX recurrence score
    Melina B Flanagan
    Department of Pathology, Magee Women s Hospital of University of Pittsburgh Medical Center, Pittsburgh, PA 15213, USA
    Mod Pathol 21:1255-61. 2008
    ..Although the Oncotype DX Recurrence Score holds potential, further validation of its independent value beyond that of histopathologic analysis is necessary before it can be implemented in clinical decision making...
  51. doi request reprint Pleomorphic lobular carcinoma in situ (PLCIS) on breast core needle biopsies: clinical significance and immunoprofile
    Mamatha Chivukula
    Department of Pathology, Magee Women s Hospital, University of Pittsburgh Medical Center, Pittsburgh, PA 15213, USA
    Am J Surg Pathol 32:1721-6. 2008
    ..PLCIS has a significant association with other high-risk lesions and invasive lobular carcinoma...
  52. doi request reprint Clinical importance of HER2 immunohistologic heterogeneous expression in core-needle biopsies vs resection specimens for equivocal (immunohistochemical score 2+) cases
    Mamatha Chivukula
    Department of Pathology, Magee Women s Hospital of UPMC, Pittsburgh, PA 115213, USA
    Mod Pathol 21:363-8. 2008
    ..However, performing fluorescence in situ hybridization on core-needle biopsies almost completely resolves the issue of heterogeneous expression of HER2...
  53. ncbi request reprint Spontaneous CD4+ T cell responses against TRAG-3 in patients with melanoma and breast cancers
    Bratislav Janjic
    Department of Medicine, Division of Hematology Oncology, University of Pittsburgh School of Medicine, Pittsburgh, PA 15213, USA
    J Immunol 177:2717-27. 2006
    ..Because of its immunodominance, peptide TRAG-3(34-48) is of particular interest for the monitoring of spontaneous immune responses in patients with TRAG-3-expressing tumors and for the development of cancer vaccines...
  54. doi request reprint Challenges of illness in metastatic breast cancer: a low-income African American perspective
    Margaret Quinn Rosenzweig
    University of Pittsburgh School of Nursing, Pittsburgh, Pennsylvania 15261, USA
    Palliat Support Care 7:143-52. 2009
    ....
  55. ncbi request reprint Phase II study of neoadjuvant docetaxel/ vinorelbine followed by surgery and adjuvant doxorubicin/cyclophosphamide in women with stage II/III breast cancer
    Steven A Limentani
    Carolinas Hematology Oncology Associates, Charlotte, NC 28203, USA
    Clin Breast Cancer 6:511-7. 2006
    ..The purpose of this study was to evaluate the combination of docetaxel plus vinorelbine as neoadjuvant chemotherapy for stage II/III locally advanced breast cancer...
  56. doi request reprint RiBBON 1 and RiBBON 2: phase III trials of bevacizumab with standard chemotherapy for metastatic breast cancer
    Joyce A O'Shaughnessy
    Baylor Charles A Sammons Cancer Center, Baylor University Medical Center, Texas Oncology, P A, US Oncology, Dallas, TX, USA
    Clin Breast Cancer 8:370-3. 2008
  57. ncbi request reprint Phase II study of neoadjuvant docetaxel, vinorelbine, and trastuzumab followed by surgery and adjuvant doxorubicin plus cyclophosphamide in women with human epidermal growth factor receptor 2-overexpressing locally advanced breast cancer
    Steven A Limentani
    Carolinas Hematology Oncology Associates, The Blumenthal Cancer Center, University of North Carolina, Charlotte, NC 28203, USA
    J Clin Oncol 25:1232-8. 2007
    ..To evaluate the combination of docetaxel, vinorelbine, and trastuzumab as neoadjuvant therapy for human epidermal growth factor receptor 2 (HER2)--overexpressing breast cancer...